Prognosis of Patients with Acute Myeloid Leukemia Regarding the Presence FLT3 Gene Mutation – a Case Report

1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.10.1182/blood-2016-03-64354427069254Search in Google Scholar

2. Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. Semin Hematol. 2015;52:200-206.10.1053/j.seminhematol.2015.03.00326111467Search in Google Scholar

3. Kottaridis PD, Gale RE, Langabeer SE, et al. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393-2398.10.1182/blood-2002-02-042012239147Open DOISearch in Google Scholar

4. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100:2387-2392.10.1182/blood-2002-01-019512239146Search in Google Scholar

5. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62-70.10.1182/blood-2015-07-60454626660427Search in Google Scholar

6. Pefani E, Panoskaltsis N, Mantalaris A, Georgiadis MC, Pistikopoulos EN. Chemotherapy drug scheduling for the induction treatment of patients with acute myeloid leukemia. IEEE Trans Biomed Eng. 2014;61:2049-2056.10.1109/TBME.2014.231322624686224Open DOISearch in Google Scholar

7. Kimby E, Nygren P, Glimelius B, et al. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 2001;40:231-252.10.1080/0284186015111632111441935Open DOISearch in Google Scholar

8. Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13:1-14.Search in Google Scholar

9. Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119:5133-5143.10.1182/blood-2011-06-36396022368270Search in Google Scholar

10. Levis M. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol. 2014;10:1571-1579.10.2217/fon.14.105608174025145428Search in Google Scholar

11. Kayser S, Levis MJ, Schlenk RF. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. Expert Rev Clin Pharmacol. 2017;10:1177-1189.10.1080/17512433.2017.138705128960095Search in Google Scholar

12. How J, Sykes J, Minden MD, et al. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. Blood Cancer J. 2013;3:e116.10.1038/bcj.2013.14367445623708641Search in Google Scholar

13. Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2016;09:693648.Search in Google Scholar

14. Deol A, Sengsayadeth S, Ahn KW, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122:3005-3014.10.1002/cncr.30140503015127315441Search in Google Scholar

15. Santos FP, Jones D, Qiao W, et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer. 2011;117:2145-2155.10.1002/cncr.25670418442921523727Search in Google Scholar